Published in Science on March 30, 1984
Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature (2010) 5.16
Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes. Diabetes Care (2010) 2.57
Immunotherapy of type 1 diabetes: where are we and where should we be going? Immunity (2010) 1.98
GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes. J Clin Invest (2002) 1.95
Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol (2013) 1.65
Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Clin Exp Immunol (2010) 1.57
Cyclosporine-induced autoimmunity. Conditions for expressing disease, requirement for intact thymus, and potency estimates of autoimmune lymphocytes in drug-treated rats. J Exp Med (1986) 1.46
It's time to consider changing the rules: the rationale for rethinking control groups in clinical trials aimed at reversing type 1 diabetes. Diabetes (2011) 1.42
Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies? Nat Rev Endocrinol (2010) 1.39
Type I (insulin dependent) diabetes: a disease of slow clinical onset? Br Med J (Clin Res Ed) (1987) 1.32
Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials. Diabetes (2013) 1.30
Coxsackievirus B3-induced myocarditis. Autoimmunity is L3T4+ T helper cell and IL-2 independent in BALB/c mice. Am J Pathol (1987) 1.17
Cyclosporin treatment for rheumatoid arthritis: a placebo controlled, double blind, multicentre study. Ann Rheum Dis (1986) 1.15
The biochemistry of diabetes. Biochem J (1988) 1.14
Rapamycin prevents the onset of insulin-dependent diabetes mellitus (IDDM) in NOD mice. Clin Exp Immunol (1992) 1.14
Effect of the immunosuppressant FK506 on glucose-induced insulin secretion from adult rat islets of Langerhans. Transplantation (1991) 1.13
No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes. Diabetes Care (2009) 1.12
Treatment of Wegener's granulomatosis with cyclosporin. Ann Rheum Dis (1987) 1.10
Preventing insulin dependent diabetes mellitus. BMJ (1993) 1.05
Islet transplantation in type 1 diabetes: ongoing challenges, refined procedures, and long-term outcome. Rev Diabet Stud (2012) 0.99
T-cell response to proinsulin and insulin in type 1 and pretype 1 diabetes. J Clin Immunol (1999) 0.98
Cyclosporine-induced deterioration in patients with AIDS. CMAJ (1989) 0.97
Persistence is the twin sister of excellence: an important lesson for attempts to prevent and reverse type 1 diabetes. Diabetes (2011) 0.96
Mechanisms of autoimmunity in insulin-dependent diabetes mellitus. Clin Exp Immunol (1988) 0.95
Immune intervention in type 1 diabetes. Semin Immunol (2011) 0.94
Current state of type 1 diabetes immunotherapy: incremental advances, huge leaps, or more of the same? Clin Dev Immunol (2011) 0.92
Evidence for a functional receptor for cyclosporin A on the surface of lymphocytes. Proc Natl Acad Sci U S A (1992) 0.91
Antigen-based immune therapeutics for type 1 diabetes: magic bullets or ordinary blanks? Clin Dev Immunol (2011) 0.90
Requirements for the induction and adoptive transfer of cyclosporine-induced syngeneic graft-versus-host disease. J Exp Med (1989) 0.90
99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: immune therapies of type 1 diabetes: new opportunities based on the hygiene hypothesis. Clin Exp Immunol (2010) 0.87
Reduction in CD4 central memory T-cell subset in costimulation modulator abatacept-treated patients with recent-onset type 1 diabetes is associated with slower C-peptide decline. Diabetes (2014) 0.87
Immunologic and metabolic biomarkers of β-cell destruction in the diagnosis of type 1 diabetes. Cold Spring Harb Perspect Med (2012) 0.85
Immunomodulation with microbial vaccines to prevent type 1 diabetes mellitus. Nat Rev Endocrinol (2010) 0.85
Photopheresis at onset of type 1 diabetes: a randomised, double blind, placebo controlled trial. Arch Dis Child (2001) 0.85
Clinical immunologic interventions for the treatment of type 1 diabetes. Cold Spring Harb Perspect Med (2012) 0.85
Mechanistic basis of immunotherapies for type 1 diabetes mellitus. Transl Res (2013) 0.84
New and future immunomodulatory therapy in type 1 diabetes. Trends Mol Med (2012) 0.83
A multivalent vaccine for type 1 diabetes skews T cell subsets to Th2 phenotype in NOD mice. Immunol Res (2011) 0.82
Critical roles of CD30/CD30L interactions in murine autoimmune diabetes. Clin Exp Immunol (2003) 0.81
Effect of FK 506 on spontaneous diabetes in BB rats. Diabetes (1990) 0.81
Reduction of spontaneous autoimmune diabetes in diabetes-prone BB rats with the novel immunosuppressant fusidic acid. Effect on T-cell proliferation and production of interferon-gamma. Immunology (1994) 0.81
Assessment of efficacy and acceptability of low dose cyclosporin in patients with rheumatoid arthritis. Ann Rheum Dis (1989) 0.80
Innate inflammation in type 1 diabetes. Transl Res (2015) 0.80
Unusual clustering of diseases in a Canadian Old Colony (Chortitza) Mennonite kindred and community. CMAJ (1988) 0.80
FK 506 prevents spontaneous diabetes in the BB rat. Transplant Proc (1991) 0.80
Inhibition of programmed cell death by cyclosporin A; preferential blocking of cell death induced by signals via TCR/CD3 complex and its mode of action. Immunology (1992) 0.80
Questioning four preconceived ideas on immunotherapy of clinical type 1 diabetes: lessons from recent CD3 antibody trials. Rev Diabet Stud (2005) 0.80
An in vitro model for cyclosporin A-induced interference of intrathymic clonal elimination. J Exp Med (1990) 0.80
The anti-arthritic and immunosuppressive effects of cyclosporin A on collagen-induced arthritis in the rhesus monkey. Clin Exp Immunol (1993) 0.79
New potential treatments for protection of pancreatic B-cell function in Type 1 diabetes. Diabet Med (2008) 0.79
Non-antigenic and antigenic interventions in type 1 diabetes. Hum Vaccin Immunother (2013) 0.78
Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset. Eur J Immunol (2016) 0.78
Effect of cyclosporin A on autoimmune tubulointerstitial nephritis in the brown Norway rat. Clin Exp Immunol (1987) 0.78
Contrasting features of T-lymphocyte-mediated diabetes in encephalomyocarditis virus-infected Balb/cBy and Balb/cCum mice. Am J Pathol (1986) 0.78
The role of immunotherapy in type I diabetes mellitus. West J Med (1987) 0.77
Effect of photopheresis on lymphocyte population in children with newly diagnosed type 1 diabetes. Clin Diagn Lab Immunol (2004) 0.77
Molecular biology of IDDM. Diabetologia (1994) 0.77
In vitro effect of cyclosporin A on immunoglobulin production and concanavalin A induced suppression in primary biliary cirrhosis. Gut (1986) 0.77
Teplizumab therapy for type 1 diabetes. Expert Opin Biol Ther (2010) 0.76
Diabetes: Immunotherapy for T1DM--still not there yet. Nat Rev Endocrinol (2013) 0.76
Antigen-based vs. systemic immunomodulation in type 1 diabetes: the pros and cons. Islets (2013) 0.76
Immunotherapy in autoimmune type 1 diabetes. Rev Diabet Stud (2012) 0.76
The case for an autoimmune aetiology of type 1 diabetes. Clin Exp Immunol (2015) 0.75
Novel diagnostic and therapeutic approaches for autoimmune diabetes--a prime time to treat insulitis as a disease. Clin Immunol (2014) 0.75
Effect of the immunosuppressant FK 506 on insulin release from adult rat islets of Langerhans. Transplant Proc (1991) 0.75
Effect of cyclosporin A treatment on the production of antibody in insulin-dependent (type I) diabetic patients. J Clin Invest (1987) 0.75
Anti-coreceptor therapy drives selective T cell egress by suppressing inflammation-dependent chemotactic cues. JCI Insight (2016) 0.75
The use of FK 506 in new-onset type I diabetes in man. Transplant Proc (1991) 0.75
The effects of cyclosporin A on glucose homeostasis and the kidney in the normal rat. J Exp Pathol (Oxford) (1990) 0.75
Progress and challenges for treating Type 1 diabetes. J Autoimmun (2016) 0.75
Monoclonal autoantibodies from insulin-dependent diabetic patients: autoantibodies against beta-cell surface or cytoplasmic antigens. Clin Exp Immunol (1990) 0.75
Effects of cyclosporin A on insulin binding and action in isolated fat cells of rat. Korean J Intern Med (1989) 0.75
Internal medicine: cyclosporine-a powerful new immunosuppressant. West J Med (1985) 0.75
Chronic cyclosporin A (CsA) nephrotoxicity in the rat: the effect of calcium blockade with verapamil. Int J Exp Pathol (1993) 0.75
The epidemiology of diabetes in childhood with special reference to the Orient: implications for mechanism of beta cell damage. Indian J Pediatr (1990) 0.75
Treatment of diabetes mellitus. Diabetologia (1992) 0.75
Immunological aspects on IDDM in children. Indian J Pediatr (1990) 0.75
Can retinopathy be prevented? Indian J Pediatr (1990) 0.75
The Burlington randomized trial of the nurse practitioner. N Engl J Med (1974) 17.02
Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA (1999) 12.75
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet (2013) 8.16
The Canadian CT Head Rule for patients with minor head injury. Lancet (2001) 7.91
Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med (1995) 7.83
The Canadian C-spine rule for radiography in alert and stable trauma patients. JAMA (2001) 7.48
Controversy in counting and attributing events in clinical trials. N Engl J Med (1979) 7.25
Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med (1995) 6.86
Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol (1991) 6.55
The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol (1995) 6.08
A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med (1999) 5.14
Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost (2000) 4.81
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med (1996) 4.70
The Burlington randomized trial of the nurse practitioner: health outcomes of patients. Ann Intern Med (1974) 4.37
A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation: a randomized controlled trial. JAMA (1999) 4.31
Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation (2000) 4.12
Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med (2003) 3.94
A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med (1993) 3.67
Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet (1994) 3.51
Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet (2000) 3.50
Decision aids for patients considering options affecting cancer outcomes: evidence of efficacy and policy implications. J Natl Cancer Inst Monogr (1999) 3.45
Effect of bromhexine on ventilatory capacity in patients with a variety of chest diseases. Lancet (1969) 3.34
Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. N Engl J Med (2000) 3.32
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev (2007) 3.28
The Ottawa patient decision aids. Eff Clin Pract (1999) 3.22
Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med (1982) 3.16
Assessing the quality of randomized trials: reliability of the Jadad scale. Control Clin Trials (1999) 2.99
Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med (1985) 2.99
Evidence-based medicine and the practicing clinician. J Gen Intern Med (1999) 2.99
Laparoscopic versus open gastric bypass: a randomized study of outcomes, quality of life, and costs. Ann Surg (2001) 2.96
Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med (1979) 2.91
Association between dinucleotide repeat in non-coding region of interferon-gamma gene and susceptibility to, and severity of, rheumatoid arthritis. Lancet (2000) 2.90
Significance testing to establish equivalence between treatments, with special reference to data in the form of 2X2 tables. Biometrics (1977) 2.87
Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest (1992) 2.81
Variation in emergency department use of cervical spine radiography for alert, stable trauma patients. CMAJ (1997) 2.79
Prognostic importance of myocardial ischemia detected by ambulatory monitoring early after acute myocardial infarction. N Engl J Med (1996) 2.69
Antithrombotic therapy in atrial fibrillation. Chest (2001) 2.62
Controlled outcome evaluation of the First Step Program: a daily physical activity intervention for individuals with type II diabetes. Int J Obes Relat Metab Disord (2004) 2.54
The effects of secretin, pancreozymin, and gastrin on insulin and glucagon secretion in anesthetized dogs. J Clin Invest (1967) 2.53
Clinical recommendations using levels of evidence for antithrombotic agents. Chest (1995) 2.52
Multicentre trial to introduce the Ottawa ankle rules for use of radiography in acute ankle injuries. Multicentre Ankle Rule Study Group. BMJ (1995) 2.50
Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med (1998) 2.49
The North American Vasovagal Pacemaker Study (VPS). A randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope. J Am Coll Cardiol (1999) 2.44
Perioperative allogeneic blood transfusion does not cause adverse sequelae in patients with cancer: a meta-analysis of unconfounded studies. Br J Surg (1998) 2.44
Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet (1988) 2.44
The rational clinical examination. Does this patient have a clinically important carotid bruit? JAMA (1993) 2.38
Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol (2000) 2.35
Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: the post-arthroplasty screening study. A randomized, controlled trial. Ann Intern Med (1997) 2.28
Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med (1989) 2.28
Dictated versus database-generated discharge summaries: a randomized clinical trial. CMAJ (1999) 2.28
What is the quality of life for survivors of cardiac arrest? A prospective study. Acad Emerg Med (1999) 2.27
Platelet-active drugs : the relationships among dose, effectiveness, and side effects. Chest (2001) 2.25
Initiating, conducting and maintaining guidelines development programs. CMAJ (1993) 2.24
Antithrombotic therapy in atrial fibrillation. Chest (1992) 2.21
A cumulative meta-analysis of the effectiveness of defibrillator-capable emergency medical services for victims of out-of-hospital cardiac arrest. Ann Emerg Med (1999) 2.19
Warfarin for atrial fibrillation. The patient's perspective. Arch Intern Med (1996) 2.18
Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am J Pathol (1993) 2.16
The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med (1994) 2.08
Antithrombotic therapy in atrial fibrillation. Chest (1995) 2.08
Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med (1999) 2.07
How should results from completed studies influence ongoing clinical trials? The CAFA Study experience. Ann Intern Med (1991) 2.06
Identification of patients most likely to benefit from implantable cardioverter-defibrillator therapy: the Canadian Implantable Defibrillator Study. Circulation (2000) 2.05
Xylazine hydrochloridine (Rompun) overdose in man. Clin Toxicol (1979) 2.00
Quality of life in stage II breast cancer: an instrument for clinical trials. J Clin Oncol (1988) 1.93
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br (2009) 1.91
Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med (2001) 1.82
Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med (1991) 1.81
Depression and risk of sudden cardiac death after acute myocardial infarction: testing for the confounding effects of fatigue. Psychosom Med (2000) 1.80
Immunological and pharmacological monitoring in the clinical use of cyclosporin A. Lancet (1981) 1.77
Increased transplantation of kidneys with multiple renal arteries in the laparoscopic live donor nephrectomy era: surgical technique and surgical and nonsurgical donor and recipient outcomes. Arch Surg (2001) 1.74
Maternal serum alpha-fetoprotein screening: report of a Canadian pilot project. CMAJ (1987) 1.72
Comparison of minimally invasive esophagectomy with transthoracic and transhiatal esophagectomy. Arch Surg (2000) 1.71
Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (2000) 1.71
Cost-effectiveness of the implantable cardioverter-defibrillator: results from the Canadian Implantable Defibrillator Study (CIDS). Circulation (2001) 1.70
Preoperative autologous donation decreases allogeneic transfusion but increases exposure to all red blood cell transfusion: results of a meta-analysis. International Study of Perioperative Transfusion (ISPOT) Investigators. Arch Intern Med (1998) 1.68
Post-myocardial infarction mortality in patients with ventricular premature depolarizations. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Pilot Study. Circulation (1991) 1.68
Expectorant action of bromhexine in chronic obstructive bronchitis. Br Med J (1970) 1.67
A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med (1986) 1.67
Evaluation of cyclosporin-phenytoin interaction with observations on cyclosporin metabolites. Br J Clin Pharmacol (1984) 1.66
The Canadian CT Head Rule Study for patients with minor head injury: rationale, objectives, and methodology for phase I (derivation). Ann Emerg Med (2001) 1.65
A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr (1993) 1.64
Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med (1982) 1.64
Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo. Am Heart J (2001) 1.62
BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost (2005) 1.60
Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study. Thromb Haemost (2001) 1.58
The effect of thrombocytopenia on experimental arteriosclerotic lesion formation in rabbits. Smooth muscle cell proliferation and re-endothelialization. J Clin Invest (1977) 1.58
The use of consensus guidelines for management of cytomegalovirus infection in renal transplantation. Kidney Int (2007) 1.57
Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet (1990) 1.56
Dual-chamber versus ventricular pacing. Critical appraisal of current data. Circulation (1996) 1.55
Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: the PROACT II trial. Neurology (2001) 1.55
Emergency department use at two Hamilton hospitals. Can Med Assoc J (1975) 1.55